Robert Barrow Receives Stock Award at Definium Therapeutics Inc (DFTX) — SEC Form 4, Feb 05, 2026

SEC Form 4 · No Market Transaction

Stock Award

Compensation grant — no market purchase or sale.

Reporting Owner

Robert Barrow

CEO

TXN 2026-02-03 · FILED 2026-02-05

Equity Position 1.1M sh 778,477 → 1,098,477

Equity Change +41.1% shares held after vs before

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Definium Therapeutics Inc

DFTX CIK 0001813814

Reporting Owner

Name	Relationship
Robert Barrow CIK 0001897557	Director CEO

Robert Barrow at Definium Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) $3,981,066

More from this insider at Definium Therapeutics Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common SharesF1	2026-02-03	A - Award/Grant	320,000 A	$0.00	—	1,098,477	Direct

Footnotes (1)

F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Show more

5%+ Holders · 13D/G 3 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Definium Therapeutics Inc

GET /v1/forms/4/0001193125-26-039571 API docs